• LOGIN
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publication
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. How Do I Manage Refractory Invasive Pulmonary Aspergillosis.
 

How Do I Manage Refractory Invasive Pulmonary Aspergillosis.

Options
  • Details
BORIS DOI
10.48350/192237
Date of Publication
June 2024
Publication Type
Article
Division/Institute

Institut für Infektio...

Author
Vergidis, Paschalis
Sendi, Parhamorcid-logo
Institut für Infektionskrankheiten (IFIK) - Forschung
Institut für Infektionskrankheiten (IFIK)
Alkhateeb, Hassan
Nguyen, M Hong
Subject(s)

500 - Science::570 - ...

600 - Technology::610...

Series
Clinical microbiology and infection
ISSN or ISBN (if monograph)
1469-0691
Publisher
Elsevier
Language
English
Publisher DOI
10.1016/j.cmi.2024.01.015
PubMed ID
38286175
Uncontrolled Keywords

Aspergillosis Hematop...

Description
BACKGROUND

Invasive aspergillosis is associated with significant morbidity and mortality in patients with hematologic malignancies and hematopoietic cell transplant recipients. The prognosis is worse among patients who have failed primary antifungal treatment.

OBJECTIVES

We aim to provide guidance on the diagnosis and management of refractory invasive pulmonary aspergillosis.

SOURCES

Using PubMed we performed a review of original articles, meta-analyses, and systematic reviews.

CONTENT

We discuss the diagnostic criteria for invasive pulmonary aspergillosis and the evidence on treatment of primary infection. We outline our diagnostic approach to refractory disease. We propose a treatment algorithm for refractory disease and discuss the role of experimental antifungal agents.

IMPLICATIONS

For patients with worsening disease while on antifungal therapy, a thorough diagnostic evaluation is required to confirm the diagnosis of aspergillosis and exclude another concomitant infection. Treatment should be individualized. Current options include switching to another triazole, transitioning to a lipid formulation of amphotericin B, or using combination antifungal therapy.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/173875
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
1-s2.0-S1198743X24000375-main.pdftextAdobe PDF990.31 KBacceptedOpen
BORIS Portal
Bern Open Repository and Information System
Build: d1c7f7 [27.06. 13:56]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo